A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)

Trial Profile

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Irinotecan (Primary) ; RRx 001 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms PAYLOAD
  • Sponsors EpicentRx
  • Most Recent Events

    • 06 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 06 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 06 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top